by Jennifer Byrne
A new clinical practice guideline jointly published by ASCO and Society for Integrative Oncology addresses the potential role of integrative pain management techniques in management of cancer-related pain in adults.
“Patients with cancer, as well as cancer … Read more
by Jason Harris
The FDA has asked Clovis Oncology to limit use of rucaparib (Rubraca) to second-line maintenance therapy for patients with recurrent ovarian cancer harboring BRCA mutations.1
The company is considering the FDA’s request. If the 2 sides
By Kristi Rosa
The FDA has granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere) for the treatment of adult patients with folate receptor α (Frα)–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received 1 to 3 prior … Read more
by Kristi Rosa
At the request of the FDA, GlaxoSmithKline (GSK) plc will restrict the second-line maintenance indication for niraparib (Zejula) to only the population of patients with recurrent ovarian cancer whose tumors harbor deleterious or suspected deleterious germline BRCA
— A response to “practice-changing data” in the first- and second-line setting
by Mike Bassett
by Mike Bassett
— Selpercatinib approved for advanced or metastatic solid tumors that progress on systemic therapy
The FDA granted accelerated approval to selpercatinib (Retevmo) for adults with locally advanced or metastatic solid tumors associated with RET gene fusions, the
… Read moreby Karen Blum
Although maintenance treatments have helped patients with ovarian cancer live longer, experts note there are still some unmet needs that must be addressed.
Karen Hanna was first diagnosed with ovarian cancer in April 2013. At the time,
by Brielle Benyon
Tafinlar plus Mekinist is now approved by the Food and Drug Administration to treat adults and children over the age of 6 who have BRAF V600-mutant advanced solid cancers.
The Food and Drug Administration (FDA) approved Tafinlar
by Lindsey Fischer
A real-world analysis showed that the proportion of women with ovarian cancer who required dose modifications or treatment discontinuations while receiving PARP inhibitors differed significantly between olaparib, niraparib, and rucaparib.
Patients with ovarian cancer treated with FDA-approved
by Ariana Pelosci
An individualized starting dose of niraparib, determined by weight and platelet count continued to demonstrate a clinical meaningful improvement in progression-free survival in newly diagnosed ovarian cancer in the first-line maintenance setting, regardless of biomarker status.
An
by Rachel N. Grisham, M.D.
As summarized in this issue of The ASCO Post, the highly anticipated results of the GOG 281/LOGS study, which randomly assigned patients with recurrent low-grade serous ovarian cancer to the MEK inhibitor trametinib vs … Read more
by Ariana Pelosci
Adverse effects associated with treatment with olaparib that led to dose reductions and interruptions did not impact survival benefit for patients with platinum-sensitive ovarian cancer.
Patients with platinum-sensitive recurrent ovarian cancer who experienced adverse effects (AEs) during
by Monica Janke, MD
In patients with ovarian cancer and pretreatment elevated CA-125 who achieved remission after frontline therapy, most recurrences are detected by rising CA-125 levels or symptoms.
In patients with ovarian cancer and pretreatment elevated CA-125 who achieved
by Brielle Benyon
Amma was developed by a cancer survivor who wanted an easier — and cheaper — way for patients to preserve their hair during chemotherapy treatment.
The Food and Drug Administration (FDA) granted clearance to Amma, a scalp-cooling
by Steve Tally
Purdue-developed imaging drug allowed surgeons to find additional cancer lesions
Left image: A drug used for fluorescent imaging during ovarian cancer surgeries, which was just approved by the FDA, lights up cancer cells “like stars against a … Read more
By Mike Bassett
— For those on active therapy, 80% had increased antibody levels, study showed
A third dose of Pfizer’s COVID-19 vaccine (BNT162b2; Comirnaty) could offer increased protection for cancer patients on active treatment, a new study suggested, as … Read more
By Mike Bassett
— Programs frequently using this treatment achieved these declines without compromising OS
Cancer programs that were more likely to use neoadjuvant chemotherapy to treat advanced ovarian cancer saw larger declines in short-term mortality versus programs with less … Read more
By Hayley Virgil
Updates to the National Comprehensive Cancer Network guidelines on the COVID-19 vaccine for patients with cancer indicate that this group should be prioritized for a third dose.
The National Comprehensive Cancer Network (NCCN) has announced a significant … Read more
By Liam Drew
PARP inhibitors are rapidly transforming the treatment of ovarian, breast, prostate and other types of cancer. To develop these drugs, researchers supported by Cancer Research UK had to decipher how blocking DNA repair could expose a weak … Read more
By Leah Lawrence
A new study estimated that a PARP inhibitor-for-all approach to treating advanced-stage ovarian cancer would be associated with high costs compared with biomarker-directed use of PARP inhibitors.1 Study researchers recommended that maintenance treatment with PARP inhibitors … Read more
